Ocular Surface Disease: An Integral Part of Glaucoma Management

Doi: 10.36351/pjo.v36i3.1064

  • Aysha Salam
Keywords: Ocular Surface Disease, Glaucoma, Benzalkonium Chloride

Abstract

Glaucoma has been a silent and symptomless disease-causing relentless loss of vision requiring lifelong treatment. It is often hard to gain patient acceptance for a condition, the treatment for which does not manifest in the form of any direct visual gains. This is in turn is compounded by the adverse effects of medication. These are most commonly poor tolerance and preservative toxicity in addition to the active ingredient which in itself can compromise a vulnerable ocular surface.1,2 Glaucoma patients are presumably at a much higher risk of developing ocular surface disease and one of the commonest reasons for that is being treated with reservative-containing medications over a prolonged period.1,2 This editorial will highlight some of the common risk factors and possible remedies in glaucoma patients manifesting with ocular surface disease.

Published
2020-05-07
How to Cite
1.
Salam A. Ocular Surface Disease: An Integral Part of Glaucoma Management. pjo [Internet]. 7May2020 [cited 2Jul.2020];36(3). Available from: http://pjo.org.pk/index.php/pjo/article/view/1064
Section
Editorial